Phase 1 Results Are Positive for Orexin Receptor ALKS 2680.

Published Date: 09 Nov 2023

Plans for a phase 2 study were prompted by preliminary findings from a phase 1 study that suggested ALKS 2680, an investigational orexin 2 receptor agonist, is safe and enhances sleep latency in narcolepsy patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot